加速药物合作精神分裂症项目参与者的基线临床特征

Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.

作者信息

Addington Jean, Liu Lu, Chu Monica, Jungert Karl, Penzel Nora, Pasternak Ofer, Farina Emily, Carrion Ricardo E, Corcoran Cheryl M, Mittal Vijay A, Strauss Gregory P, Yung Alison R, Alameda Luis, Arango Celso, Borders Owen, Bouix Sylvain, Breitborde Nicholas J K, Broome Matthew R, Cadenhead Kristin S, Castillo-Passi Rolando I, Chen Eric Yu Hai, Choi Jimmy, Coleman Michael J, Conus Philippe, Diaz-Caneja Covadonga M, Ellman Lauren M, Poli Paolo Fusar, Gaspar Pablo A, Gerber Carla, Glenthøj Louise Birkedal, Horton Leslie E, Hui Christy Lai Ming, Kambeitz Joseph, Kambeitz-Ilankovic Lana, Kapur Tina, Kelly Sinead, Kerr Melissa J, Keshavan Matcheri S, Kim Minah, Kim Sung-Wan, Koutsouleris Nikolaos, Kwon Jun Soo, Langbein Kerstin, Lewandowski Kathryn E, Mamah Daniel, Marcy Patricia J, Mathalon Daniel H, Mourgues Catalina, Nordentoft Merete, Nunez Angela R, Pearlson Godfrey D, Perez Jesus, Perkins Diana O, Powers Albert R, Rogers Jack, Sabb Fred W, Schiffman Jason, Seitz-Holland Johanna, Shah Jai L, Silverstein Steven M, Smesny Stefan, Stone William S, Thompson Judy L, Upthegrove Rachel, Verma Swapna, Wang Jijun, Wolf Daniel H, Zhang Tianhong, Addamo Lauren, Buccilli Kate, Dwyer Dominic, Todd Sophie, Cho Youngsun T, Fontenau Clara, Tamayo Zailyn, Bearden Carrie E, Kane John M, McGorry Patrick D, Kahn Rene S, Shenton Martha E, Woods Scott W, Calkins Monica E

机构信息

Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB T2N 4Z6, Canada.

Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, United States.

出版信息

Schizophr Bull Open. 2025 Aug 25;6(1):sgaf012. doi: 10.1093/schizbullopen/sgaf012. eCollection 2025 Jan.

DOI:10.1093/schizbullopen/sgaf012

PMID:40861307

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12377803/

Abstract

BACKGROUND

This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants.

METHODS

The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs. Key measures include the Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the Structured Interview for Psychosis-Risk Syndromes, which determined CHR criteria and the severity of attenuated psychotic symptoms (APS). Other measures included the Structured Clinical Interview for DSM-5, scales to assess negative symptoms, depression, suicidal ideation, substance use, social and role functioning, and a selection of patient-reported outcomes.

RESULTS

CHR participants presented with more severe ratings on all clinical measures and poorer functioning relative to the CC. There were a few significant small associations between measures of APS and other clinical measures.

CONCLUSION

The results from this study support previous research indicating that CHR individuals face serious clinical challenges beyond the risk of developing psychosis. Findings indicate significant associations among various clinical measures, underscoring the complex nature of the CHR population. Limitations are acknowledged, including the preliminary nature of the data and the need for more in-depth analyses from AMP SCZ papers already in progress. Future work will focus on longitudinal data and further exploration of clinical variables and their relationship with biomarkers.

摘要

背景

本文聚焦于加速药物合作精神分裂症（AMP SCZ）项目参与者的基线临床特征。AMP SCZ项目旨在对总共2040名临床高危（CHR）参与者和652名社区对照（CC）参与者的一系列临床变量和生物标志物进行研究。

方法

所分析的数据集包括1642名精神病临床高危个体和519名CC个体。关键测量指标包括与精神病风险综合征结构化访谈相协调的高危精神状态综合评估的阳性症状和诊断标准，该标准确定了CHR标准以及精神病性症状衰减（APS）的严重程度。其他测量指标包括DSM-5结构化临床访谈、评估阴性症状、抑郁、自杀观念、物质使用、社会和角色功能的量表，以及一系列患者报告的结果。

结果

与CC个体相比，CHR参与者在所有临床测量指标上的评分更高，功能更差。APS测量指标与其他临床测量指标之间存在一些显著的小关联。

结论

本研究结果支持先前的研究，表明CHR个体面临着除发展为精神病风险之外的严重临床挑战。研究结果表明各种临床测量指标之间存在显著关联，突显了CHR人群的复杂性。承认存在局限性，包括数据的初步性质以及需要对正在进行的AMP SCZ论文进行更深入的分析。未来的工作将集中在纵向数据以及对临床变量及其与生物标志物关系的进一步探索上。